NCT04624321

Brief Summary

The overall aim of the study is to evaluate a digital lifestyle intervention that has been developed in an academic setting at the University of Gothenburg, Sweden. The tool is based on self-affirmation theory and has large emphasis on self-reflection to enable sustainable lifestyle changes. The effects of the tool on HbA1c, reflecting long-term blood glucose, will be evaluated in patients with type 2 diabetes. The study will contain two phases. The study consists of a three-month period in which participants are randomly assigned to usual care or access to the intervention tool, followed by an open-label three-year observation period during which participants have access to the tool in addition to ordinary healthcare and are compared with matched controls on usual care.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for not_applicable diabetes-mellitus-type-2

Timeline
7mo left

Started Jan 2021

Longer than P75 for not_applicable diabetes-mellitus-type-2

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress90%
Jan 2021Dec 2026

First Submitted

Initial submission to the registry

October 30, 2020

Completed
11 days until next milestone

First Posted

Study publicly available on registry

November 10, 2020

Completed
2 months until next milestone

Study Start

First participant enrolled

January 1, 2021

Completed
6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Last Updated

July 16, 2025

Status Verified

July 1, 2025

Enrollment Period

6 years

First QC Date

October 30, 2020

Last Update Submit

July 13, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • Change of long-term blood glucose concentration measured as glycated hemoglobin at 3 months

    Intraindividual change of long-term blood glucose concentration measured as glycated hemoglobin (HbA1c) at 3 months relative to baseline compared between participants with access to the tool and on usual care.

    3 months

  • Change of long-term blood glucose concentration measured as glycated hemoglobin at one year

    Intraindividual change of long-term blood glucose concentration measured as glycated hemoglobin (HbA1c) at one year relative to baseline between participants who use the tool as recommended and matched controls on usual care

    One year of the open-label observation period

Secondary Outcomes (6)

  • Change of long-term blood glucose concentration measured as glycated hemoglobin at three years

    Three years of the open-label observation period

  • Body weight

    3 months, 1 year and 3 years

  • Insulin resistance

    3 months, 1 year and 3 years

  • Fasting blood glucose concentration

    3 months, 1 year and 3 years

  • Physical activity in calories per day

    3 years

  • +1 more secondary outcomes

Other Outcomes (1)

  • Change of long-term blood glucose concentration measured as glycated hemoglobin in participants with and without Mild Obesity-related Diabetes, respectively.

    1 year and 3 years

Study Arms (2)

Access to tool

EXPERIMENTAL

Access to the digital tool. They use the tool at their own and do the different themes that are available. They are recommended to use it at least every other week.

Behavioral: Health and lifestyle tool

Usual care

PLACEBO COMPARATOR

They are followed by their ordinary healthcare provider.

Other: Usual care

Interventions

Health and lifestyle tool used online

Access to tool

Usual care at ordinary healthcare provider

Usual care

Eligibility Criteria

Age35 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with type 2 diabetes at or above 35 years of age
  • Diagnosis of diabetes mellitus was based on prior documentation or treatment with anti-hyperglycemic medication or diagnosed according to the WHO criteria (random plasma glucose \>11.1 mmol/L or fasting glucose \>7.0 mmol/L or HbA1C ≥6.5%).
  • written informed consent.

You may not qualify if:

  • type 1 diabetes, MODY or secondary diabetes
  • conditions or treatments that in the judgement of the Investigator could affect the study evaluation
  • inability to understand written Swedish
  • connection with the study team, funders, authorities, universities or other public or private bodies in such a way that specific interests in the study outcomes could be suspected.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Clinical Research Center

Malmo, Skåne County, 20502, Sweden

Location

Related Publications (2)

  • Salunkhe VA, Sinha N, Ahlqvist E, Prasad RB, Johansson S, Abrahamsson B, Rosengren AH. Digital lifestyle treatment improves long-term metabolic control in type 2 diabetes with different effects in pathophysiological and genetic subgroups. NPJ Digit Med. 2023 Oct 26;6(1):199. doi: 10.1038/s41746-023-00946-0.

  • Dwibedi C, Abrahamsson B, Rosengren AH. Effect of Digital Lifestyle Management on Metabolic Control and Quality of Life in Patients with Well-Controlled Type 2 Diabetes. Diabetes Ther. 2022 Mar;13(3):423-439. doi: 10.1007/s13300-022-01214-2. Epub 2022 Feb 12.

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

Health

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

Population Characteristics

Study Officials

  • Anders Rosengren

    Region Skåne

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: The study has an initial 3-month randomization phase with two parallel arms, one randomized to access the lifestyle tool and one randomized to a wait list on usual care. After that 3-month period, all participants will get access to the tool, independent of previous randomization assignment, and are followed over three years in an open-label observation period where changes to HbA1c and secondary variables are compared against matched controls on usual care.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 30, 2020

First Posted

November 10, 2020

Study Start

January 1, 2021

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Last Updated

July 16, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will share

Individual participant data that underlie the results will be shared after deidentification.

Time Frame
Data will be available after publication.
Access Criteria
To researchers who provide a methodologically sound proposal in order to achieve the aims of that proposal. Proposals should be directed by email to internetverktyg@gu.se

Locations